2024-03-262024-03-262018-05-03Aydın, B. vd. (2018). ''Modulation of nesfatin-1-induced cardiovascular effects by the central cholinergic system''. Neuropeptides, 70, 9-15.0143-4179https://www.sciencedirect.com/science/article/pii/S0143417918300386https://hdl.handle.net/11452/40626Nesfatin-1, a peptide whose receptor is yet to be identified, has been shown to be involved in the modulation of feeding, stress, and metabolic responses. Recently, increasing evidence has supported a modulatory role of nesfatin-1 in cardiovascular activity. We have previously reported that nesfatin-1 causes an increase in blood pressure in normotensive and hypotensive rats by increasing plasma catecholamine, vasopressin, and renin levels. Recent reports suggest that nesfatin-1 may activate the central cholinergic system. However, there is no evidence showing an interaction between central nesfatin-1 and the cholinergic system. Therefore, this study aimed to determine whether the central cholinergic system may have a functional role in the nesfatin-1-induced cardiovascular effect observed in normotensive rats. Intracerebroventricular injection of nesfatin-1 caused short-term increases in mean arterial pressure and heart rate responses including bradycardic/tachycardic phases in normotensive animals. Central injection of nesfatin-1 increased the acetylcholine and choline levels in the posterior hypothalamus, as shown in microdialysis studies. Central pretreatment with the cholinergic muscarinic receptor antagonist atropine and/or nicotinic receptor antagonist mecamylamine blocked nesfatin-1-induced cardiovascular effects. In conclusion, the results show that centrally administered nesfatin-1 produces a pressor effect on blood pressure and heart rate responses including bradycardic/tachycardic phases in normotensive rats. Moreover, according to our findings, the central cholinergic system can modulate nesfatin-1-evoked cardiovascular activity.eninfo:eu-repo/semantics/closedAccessEndocrinology & metabolismNeurosciences & neurologyNesfatin-1Blood pressureHeart ratePosterior hypothalamic choline/acetylcholineCholinergic muscarinic and nicotinic receptorsThromboxane A2 analogInjected cdp-cholineBlood-pressureHypotensive ratsConscious ratsSolitary tractNeuronsBrainInvolvementNucleusAcetylcholineAnimalsBlood pressureBrainCalcium-binding proteinsCatecholaminesCholinergic agentsDNA-binding proteinsHeart rateHypotensionMaleMecamylamineNerve tissue proteinsRats, sprague-dawleyVasoconstrictor agentsVasopressinsArticle0004409574000022-s2.0-850466343629157029751997https://doi.org/10.1016/j.npep.2018.05.001Endocrinology & metabolismNeurosciencesSubfornical Organ; Animals; Hypothalamic Paraventricular NucleusAcetylcholineCholineMuscarinic receptorNesfatin 1NeuropeptideNicotinic receptorUnclassified drugAcetylcholineCalcium binding proteinCatecholamineCholinergic receptor stimulating agentDNA binding proteinMecamylamineNerve proteinNucleobindinVasoconstrictor agentVasopressin derivativeAdultAnimal experimentAnimal tissueArticleBradycardiaCardiovascular effectCholinergic systemControlled studyHeart rateMaleMean arterial pressureNonhumanPosterior hypothalamusPriority journalRatTachycardiaAnimalBloodBlood pressureBrainDrug effectHypotensionMetabolismSprague dawley rat1532-2785